Particulate hyaluronic acid and flavonoid formulations for cellular delivery of bioactive agents

Patent metadata

Field	Value
Publication number	US-9226899-B2
Application number	US-201414292734-A
Country	US
Kind code	B2
Filing date	May 30, 2014
Priority date	Aug 11, 2009
Publication date	Jan 5, 2016
Grant date	Jan 5, 2016

Abstract

There is presently provided a suspension of immiscible particles in a solution, wherein the particles comprise an agglomeration of a bioactive agent, for example an anti-cancer agent; and a plurality of conjugates of a hyaluronic acid and a flavonoid, for example a catechin-based flavonoid, wherein the particles are on average from about 15 nm to about 300 nm in diameter and wherein the bioactive agent is releasably retained in the particles by the flavonoid. The suspension is useful for delivery of the bioactive agent to cells, including cancer cells. There are also provided a therapeutic formulation comprising the suspension, as well as methods for using the suspension and therapeutic formulation, including for delivery of a bioactive agent to a cell and for treating a disease, including cancer.

First claim

What is claimed is:

1. A method for delivery of a bioactive agent to a cell, the method comprising contacting the cell with a suspension of immiscible particles in an aqueous solution, wherein the particles comprising an agglomeration of:
a bioactive agent; and
a plurality of conjugates of a hyaluronic acid and a flavonoid;
the particles having a hydrated interior and having an average diameter of from about 15 nm to about 300 nm, the bioactive agent being releasably retained in the particles by the flavonoid.

2. The method of claim 1 , wherein the bioactive agent is delivered intracellularly.

3. The method of claim 1 wherein the cell is a cancer cell.

4. The method of 1 wherein the cell is in vitro.

5. The method of claim 1 wherein the cell is in vivo, the method further comprising administering the suspension to a subject in an amount effective for the treatment of cancer.

6. A method of formulating a suspension of immiscible particles comprising combining in an aqueous solution:
a. 0.01% w/v to about 1.0% w/v of a bioactive agent; and
b. 0.05 μg/ml to about 5000 μg/ml of conjugates of a hyaluronic acid and a flavonoid;
to form the suspension of particles the particles comprising an agglomeration of the bioactive agent and the conjugates of hyaluronic acid and a flavonoid, the particles having a hydrated interior and having an average diameter of from about 15 nm to about 300 nm, the bioactive agent being releasably retained in the particles by the flavonoid.

7. The method of claim 6 comprising combining an endosomolytic agent with the bioactive agent and the conjugates of a hyaluronic acid and a flavonoid to form the suspension and wherein the particles further comprise the endosomolytic agent.

8. The method of claim 6 further comprising formulating the suspension into a therapeutic formulation.

9. The method of claim 1 wherein the flavonoid is a catechin-based flavonoid.

10. The method of claim 9 wherein the flavonoid is epigallocatechin gallate.

11. The method of claim 1 wherein the bioactive agent is an anti-cancer agent.

12. The method of claim 1 wherein the bioactive agent is a protein.

13. The method of claim 1 wherein the bioactive agent is an intrabody.

14. The method of claim 1 wherein the bioactive agent is Granzyme B.

15. The method of claim 1 wherein the particles further comprise an endosomolytic agent.

16. The method of claim 6 wherein the bioactive agent is releasably retained in the particles by a hydrophobic bond or an ionic bond between the flavonoid and the bioactive agent.

17. The method of claim 6 wherein the particles are on average from about 50 nm to about 100 nm in diameter.

18. The method of claim 6 wherein the hyaluronic acid has a molecular weight of from about 5000 to about 10000000 daltons.

Assignees

• Agency Science Tech & Res

Inventors

• Kurisawa Motoichi
• Ng Shengyong
• Chung Joo Eun

Classifications

• A61K9/10 Primary

  Dispersions; Emulsions · CPC title

• A61K47/61

  the organic macromolecular compound being a polysaccharide or a derivative thereof · CPC title

• A61K31/7048

  having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin} · CPC title

• A61K31/4706

  4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine · CPC title

• C07K16/18

  against material from animals or humans · CPC title